Sovremennye aspekty lecheniya metabolicheskogosindroma
Abstract
It is known that the metabolic syndrome precedes the occurrence of cardiovascular pathology and type 2 diabetes, and increases
the risk for the associated death. However, this condition is reversible, and may be cured, or the reduction of its main symptoms could
be observed. The article demonstrates the current approach to the therapy of the metabolic syndrome.
the risk for the associated death. However, this condition is reversible, and may be cured, or the reduction of its main symptoms could
be observed. The article demonstrates the current approach to the therapy of the metabolic syndrome.
References
1. Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению // РМЖ. - 2001. - № 9 (2). - С. 56-60.
2. Бутрова С.А. Терапия ожирения: влияние Орлистата (Ксеникал) на кардиометаболические факторы риска // Ожирение и метаболизм. - 2008. - № 3. - С. 20-23.
3. Мельниченко Г.А., Комшилова К.А., Берковская М.А. Опыт применения препарата Орсотен (орлистат) у больных ожирением // Ожирение и метаболизм. - 2010. - № 1. - С. 46-50.
4. Чазова И.Е., Мычка В.Б. Метаболический синдром // Consilium medicum. - 2002. - № 11.
5. Alberti K.G.M.M., Eckel R.H., Grundy S.M. et al. Harmonizing the Metabolic Syndrome: А Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity // Circulation. - 2009. - № 120 (16). - Р. 1640-1645.
6. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey // JAMA. - 2002. - № 287 (3). - Р. 356-359.
7. Fukuhara A., Matsuda M. et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin // Science. - 2005. - № 307. - Р. 426-430.
8. Graham T.E., Qin Yang et al. Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese and Diabetic Subjects // NEJM. - 2006. - № 354. - Р. 2552-2563.
9. Kaplan N.M. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension // Arch. Intern. Med. - 1989. - № 149. - Р. 1514-1520.
10. Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and Metabolic Syndrome // Arterioscler. Thromb. Vasc. Biol. - 2004. - № 24. - Р. 29-33.
11. McTernan C.L., McTernan P.G., Harte A.L. et al. Resistin, central obesity, and type 2 diabetes // Lancet. - 2002. - № 36. - Р. 46-47.
12. Mertens I., Van Gaal L.F. Obesity, haemostasis and the fibrinolytic system // Obes. Rev. - 2002. - № 3(2). - Р. 85-101.
13. Montague C.T., Prins J., Sanders B. et al. Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution // Diabetes. - 1997. - № 46. - Р. 342-347.
14. Reaven G.M. Banting lecture: role of insulin resistance in human disease // Diabetes. - 1988. - № 37. - Р. 1595-1607.
15. Rucker D., Padwal R., Li S.K., Curioni C., Lau D.C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis // BMJ. - 2007. - № 335. - Р. 1194-1199.
16. Steppan C.M., Bailey S.T., Bhat S. et al. The hormone resistin links obesity to diabetes // Nature. - 2001. - № 409. - Р. 307-312.
Review
For citations:
Sovremennye aspekty lecheniya metabolicheskogosindroma. Obesity and metabolism. 2011;8(3):31-37. (In Russ.)
Views:
492
Email this article 
